- Partnership with Sumitomo Corporation Group Subsidiary... Research Results Shared at International Conferences with Major Institutions in Korea and Japan
- Korea University Anam Hospital Introduces Comprehensive Genomic Analysis Beyond Conventional Panel Testing
InnoCras, a company specializing in comprehensive genomic analysis for precision oncology, announced that it has presented the results of its research based on whole-genome analysis, conducted jointly with major cancer centers and university hospitals in Japan, at an international conference.
In February, InnoCras entered into a strategic partnership with Summit Pharmaceuticals International (SPI), a subsidiary of the Sumitomo Corporation Group, and jointly designed a clinical research model based on precision genomic analysis for cancer patients in Japan. Building on this, the company has been actively conducting analyses using real patient data in collaboration with leading medical institutions, including the National Cancer Center Japan and Keio University Hospital.
From June 28 to June 30, InnoCras presented the first results of its joint research with the National Cancer Center Japan at the International Conference on Precision Medicine, co-hosted by the Japanese Cancer Association (JCA) and the American Association for Cancer Research (AACR) in Kyoto, Japan. At this event, InnoCras shared practical data with global medical professionals and researchers, focusing on cases where its precision cancer genomic analysis solution, 'CancerVision,' was applied to 20 cancer patients at the National Cancer Center Japan.
Subsequently, at the Society of Clinical Biobank conference held in Tokyo from July 4 to July 5, InnoCras introduced the results of its joint research with Keio University Hospital. In this presentation, the company covered not only 'CancerVision,' but also real-world applications of 'MRDVision,' a solution for precise detection of minimal residual disease (MRD) after cancer treatment.
'MRDVision' is a next-generation analysis solution that detects minimal residual cancer cells remaining in the body after treatment with high sensitivity, representing an innovative technology that contributes to precise assessment of treatment response and prediction of recurrence.
Meanwhile, in Korea, Korea University Anam Hospital is moving beyond conventional panel analysis and is beginning to adopt comprehensive genomic analysis for clinical application. InnoCras is supporting this initiative by providing technical consulting and computing power.
Professor Ahn Sangjeong, head of the pathology department at Korea University Anam Hospital, stated, "In line with the changing times, Korea University Hospital is working with InnoCras to drive innovation so that patients can receive treatments tailored to their own genomic data," adding, "This will serve as an opportunity for Korea's medical infrastructure to lead at a global level."
An InnoCras representative commented, "This collaboration with major institutions in Korea and Japan is a meaningful joint research effort that goes beyond simple technology adoption to verify its practical applicability in real clinical settings," and added, "We will continue to work with global partners to deliver tangible value in precision diagnostics at the point of care."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
